An AI tool called Muse aims to optimize clinical trial patient recruitment and accelerate the development of new therapies.

B.Riley Financial analyst Mayank Mamtani has maintained their bullish stance on NVAX stock, giving a Buy rating on November 13.Don't Miss our ...

Sanofi, and Molecular Partners AG. According to TipRanks, Vosser has an average return of 5.0% and a 49.18% success rate on recommended stocks. Merck KGaA has an analyst consensus of Strong Buy, with ...